Evidence Table H2. CONTINUOUS outcomes for class ANTI-BACTERIAL (ORAL).

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	H.01.01			**Clindamycin**		**Vehicle**		
56 Parallel	N=98 Mod/sev	**Comedones change (%)**	Short (6)	Percent change: -48		Percent change: -22		**0.05**
		Pustules change (%)	Short (6)	Percent change: -70		Percent change: -38		**0.01**
		Comedones change (%)	Mid (10)	Percent change: -55		Percent change: -35		**NS**
		Pustules change (%)	Mid (10)	Percent change: -78		Percent change: -48		**0.01**
		Comedones change (%)	Long (13	Percent change: -48		Percent change: -22		**0.05**
		Pustules change (%)	Long (13	Percent change: -80		Percent change: -28		**0.01**
	H.01.02			**Clindamycin**		**Tetracycline**		
265 ↑ Parallel	N=48 Mod	**Comedones (count)** Baseline counts: 38 (Target) / 36 (Comparator)	Short (4)	Percent Change*: -32		Percent Change*: -42		
		Overall change/physician (rating)	Short (4)	Measure: 2		Measure: 2		
		Pustules (count) Baseline counts: 27 (Target) / 20 (Comparator)	Short (4)	Percent Change*: -56		Percent Change*: -75		
		Severity (panzer)	Short (4)	Measure: 2		Measure: 1		
		Comedones (count) Baseline counts: 38 (Target) / 36 (Comparator)	Mid (8)	Percent Change*: -47		Percent Change*: -64		
		Overall change/physician (rating)	Mid (8)	Measure: 2		Measure: 2		
		Pustules (count) Baseline counts: 27 (Target) / 20 (Comparator)	Mid (8)	Percent Change*: -67		Percent Change*: -90		
		Severity (panzer)	Mid (8)	Measure: 2		Measure: 1		
	H.02.01			**Demethylchlortetracycline**		**Placebo**		
312 ↑ Parallel	N=66 Mild/mod/sev	**Overall change/patient (score)**	Short (4)	Measure: 4 (3.6)		Measure: 3 (4.8)		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
312 ↑ N=66 Parallel Mild/mod/sev		**Severity change/photo (score)** Count location: Entire face.	Short (4)	Measure: 1 (2.5)		Measure: 1 (2.4)		**NS**
	H.02.02			**Demethylchlortetracycline**		**Phenethicillin**		
312 ↑ N=66 Parallel Mild/mod/sev		**Overall change/patient (score)**	Short (4)	Measure: 4 (3.6)		Measure: 3 (4.8)		**NS**
		Severity change/photo (score) Count location: Entire face.	Short (4)	Measure: 1 (2.5)		Measure: 1 (3.1)		**NS**
	H.03.01			**Doxycycline**		**Placebo**		
273 ↓ N=62 Cross-over Mild		**Total inflammatory [phase i] (count)** Baseline counts: 14 (Target) / 13 (Comparator)	Short (4)	Percent Change*: -36	*.001*	Percent Change*: 12	*NS*	
		Total inflammatory [phase ii] (count) Baseline counts: 12 (Target) / 12 (Comparator)	Short (4)	Percent Change*: -24	*.05*	Percent Change*: 02	*NS*	
	H.03.02			**Doxycycline**		**Fusidic acid cream**		
1 ↑ N=110 Parallel Mild/mod		**Total lesions (count)** Count location: Half face.	Short (6)	Raw count: 4 (10.)	*.001*	Raw count: 5 (7.)	*.001*	**NS***
		Total lesions (count)	Mid (10)	Raw count: 4 (10.)	*.001*	Raw count: 4 (7.)	*.001*	**NS***
	H.03.03			**Doxycycline + placebo**		**Erythromycin stearate + placebo**		
25 ↑ N=56 Parallel Mod		**Inflammatory change (%)** Count location: Entire face.	Short (6)	Percent change: 16	*.001*	Percent change: 15	*.001*	**NS**
		Severity (kligman)	Short (6)	Measure: 1		Measure: 1		
	H.03.04			**Doxycycline**		**Minocycline**		
311 N=18 Parallel Mild/mod		**Severity change (smit)**	Mid (12)	Measure: 22 (10.)		Measure: 23 (15.)		**NS**
	H.03.04			**Doxycycline + placebo**		**Minocycline + placebo**		
257 N=79 Parallel Mod/sev		**Closed comedones (count)** Baseline counts: 21 (Target) / 18 (Comparator)	Short (4)	Percent Change*: -12		Percent Change*: -17		**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
257 Parallel	N=79 Mod/sev	**Open comedones (count)** Baseline counts: 24 (Target) / 24 (Comparator)	Short (4)	Percent Change*: -08		Percent Change*: -08		**NS***
		Papules (count) Baseline counts: 31 (Target) / 35 (Comparator)	Short (4)	Percent Change*: -45		Percent Change*: -37		**NS***
		Pustules (count) Baseline counts: 13 (Target) / 20 (Comparator)	Short (4)	Percent Change*: -46		Percent Change*: -50		**NS***
		Total lesions (count) Baseline counts: 90 (Target) / 98 (Comparator)	Short (4)	Percent Change*: -31		Percent Change*: -34		**NS***
		Closed comedones (count) Baseline counts: 21 (Target) / 18 (Comparator)	Mid (12)	Percent Change*: -41		Percent Change*: -44		**NS***
		Open comedones (count) Baseline counts: 24 (Target) / 24 (Comparator)	Mid (12)	Percent Change*: -38		Percent Change*: -29		**NS***
		Papules (count) Baseline counts: 31 (Target) / 35 (Comparator)	Mid (12)	Percent Change*: -61		Percent Change*: -67		**NS***
		Pustules (count) Baseline counts: 13 (Target) / 20 (Comparator)	Mid (12)	Percent Change*: -62		Percent Change*: -60		**NS***
		Total lesions (count) Baseline counts: 90 (Target) / 98 (Comparator)	Mid (12)	Percent Change*: -44		Percent Change*: -49		**NS***
	H.03.04			**Doxycyline**		**Minocyline**		
155 Parallel	N=43 Mild/mod/sev	**Cysts change (%)** Count location: Neck anterior to sternomastoid muscles and face, e.	Mid (12)	Percent change: -89		Percent change: -81		**NS**
		Nodules change (%)	Mid (12)	Percent change: -73		Percent change: -72		**NS**
		Papules changes (%)	Mid (12)	Percent change: -67		Percent change: -67		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
155 Parallel	N=43 Mild/mod/sev	**Pustules change (%)** Count location: Neck anterior to sternomastoid muscles and face, e.	Mid (12)	Percent change: -84		Percent change: -82		**NS**
		Severity change (% Wright)	Mid (12)	Measure: -66		Measure: -68		**NS**
		Total lesions (%)	Mid (12)	Percent change: -59		Percent change: -59		**NS**
	H.04.02			**Erythromycin (stearate)**		**Erythromycin (base)**		
24 ↑ Parallel	N=40 Mod	**Papules (count)** Count location: Face.	Short (2)	Raw count: 13 (7.21)	*.001*	Raw count: 21 (9.6)	*.001*	**0.01**
	H.04.03			**Erythromycin + placebo**		**Tetracycline + placebo**		
125 ↑ Parallel	N=178 Mild/mod	**Closed comedones change (%)**	Short (4)	Percent change: -7		Percent change: -24		**0.05**
		Papules change (%)	Short (4)	Percent change: -39		Percent change: -34		**NS**
		Pustules change (%)	Short (4)	Percent change: -57		Percent change: -50		**NS**
		Closed comedones change (%)	Mid (12)	Percent change: -17		Percent change: -36		**NS**
		Open comedones change (%)	Mid (12)	Percent change: -26		Percent change: -31		**NS**
		Papules change (%)	Mid (12)	Percent change: -60		Percent change: -62		**NS**
		Pustules change (%)	Mid (12)	Percent change: -73		Percent change: -65		**NS**
	H.04.03			**Erythromycin acistrate**		**Tetracycline**		
36 ↑ Parallel	N=60 Mod/sev	**Back severity (harcup/median)** Count location: Back.	Mid (12)	Measure: 2	*.05*	Measure: 2	*.05*	**NS**
		Chest severity (harcup/median) Count location: Chest.	Mid (12)	Measure: 2	*.05*	Measure: 1	*.05*	**NS**
		Face/neck severity (harcup/median) Count location: Face/neck.	Mid (12)	Measure: 2		Measure: 1	*.05*	
		Back severity (harcup/median) Count location: Back.	Long (24	Measure: 2	*.05*	Measure: 2	*.05*	**NS**
		Chest severity (harcup/median) Count location: Chest.	Long (24	Measure: 1	*.05*	Measure: 1	*.05*	**NS**
		Face/neck severity (harcup/median) Count location: Face/neck.	Long (24	Measure: 1	*.05*	Measure: 1	*.05*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	H.05.01			**Minocycline**		**Placebo**		
161 ↑ N=43 Cross-over		**Severity (witkowski)**	Short (5)	Measure: -40	*.05*	Measure: -16	*NS*	
		Severity change [phase ii] (group %)	Short (5)	Measure: -43	*.05*	Measure: -24	*NS*	
	H.05.02			**Minocycline**		**Clindamycin**		
268 ↑ N=80 Parallel Mod/sev		**Inflammatory (count)** Count location: Face + or - other. Baseline counts: 80 (Target) / 80 (Comparator)	Short (4)	Percent Change*: -23		Percent Change*: -30		**NS***
		Non-inflammatory (count) Count location: Face + or - other. Baseline counts: 62 (Target) / 60 (Comparator)	Short (4)	Percent Change*: -27		Percent Change*: -25		**NS***
		Overall assessment (vas) Count location: Face + or - other.	Short (4)	Measure: 27 (20.)		Measure: 29 (20.)		**NS**
		Inflammatory (count) Count location: Face + or - other. Baseline counts: 80 (Target) / 80 (Comparator)	Mid (12)	Percent Change*: -44	*.0001*	Percent Change*: -31	*.0001*	**NS**
		Non-inflammatory (count) Count location: Face + or - other. Baseline counts: 62 (Target) / 60 (Comparator)	Mid (12)	Percent Change*: -40	*.0002*	Percent Change*: -33	*.0002*	**NS**
		Overall assessment (vas) Count location: Face + or - other.	Mid (12)	Measure: 15 (10.)	*.0001*	Measure: 18 (20.)	*.0001*	**NS**
	H.05.02			**Minocycline + placebo**		**Clindamycin phosphate + placebo**		
307 ↑ N=64 Parallel Mod/sev		**Inflammatory (count)**	Short (4)	Raw count: 38 (5.)		Raw count: 35 (5.)		**#Error**
		Non-inflammatory (count) Count location: Face.	Short (4)	Raw count: 51 (4.1)	*NS*	Raw count: 46 (4.)	*NS*	**NS**
		Severity (leeds)	Short (4)	Measure: 1 (0.6)		Measure: 1 (0.5)		**NS**
	H.05.04			**Minocycline**		**Tetracycline**		
171 N=104 Cross-over Mod/sev		**Severity reduction (cumulative %)**	Short (6)	Measure: 52		Measure: 28		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
298 ↑ Parallel	N=62 Mod/sev	**Severity/investigator (samuelson)**	Short (6)	Measure: 4 (2.3)		Measure: 4 (1.66)		**NS**
		Severity/patient (samuleson)	Short (6)	Measure: 4 (2.2)		Measure: 4 (1.55)		**NS**
171 Cross-over	N=104 Mod/sev	**Severity reduction (cumulative %)**	Mid (12)	Measure: 75		Measure: 70		**NS**
298 ↑ Parallel	N=62 Mod/sev	**Severity/investigator (samuelson)**	Mid (12)	Measure: 3 (1.99)		Measure: 3 (2.2)		**NS**
		Severity/patient (samuelson)	Mid (12)	Measure: 3 (1.9)		Measure: 3 (1.98)		**NS**
72	N=100	**Comedones (count)** Count location: Right. Baseline counts: 35 (Target) / 30 (Comparator)	Long (19	Percent Change*: -42		Percent Change*: -36		
		Cysts (count) Count location: Right. Baseline counts: 1 (Target) / 1 (Comparator)	Long (19	Percent Change*: -62		Percent Change*: -57		
		Papules (count) Count location: Right. Baseline counts: 16 (Target) / 11 (Comparator)	Long (19	Percent Change*: -48		Percent Change*: -41		
		Pustules (count) Count location: Right. Baseline counts: 9 (Target) / 14 (Comparator)	Long (19	Percent Change*: -60		Percent Change*: -72		
171 Cross-over	N=104 Mod/sev	**Severity reduction (cumulative %)**	Long (24	Measure: 100		Measure: 100		**NS**
		Time to severity reduction (days)	Long (24	Measure: 63		Measure: 78		**NS**
	H.06.02			**Oxytetracycline (oral) + vehicle**		**Benzoyl peroxide + placebo (oral)**		
255 Parallel	N=69 Mod	**Back severity (leeds)** Count location: Back.	Mid (12)	Measure: 0 (0.19)	*.02*	Measure: 0 (0.41)	*NS*	**NS**
		Chest severity (leeds) Count location: Chest.	Mid (12)	Measure: 0 (0.13)	*NS*	Measure: 0 (0.4)	*NS*	**NS**
		Face severity (leeds) Count location: Face.	Mid (12)	Measure: 0	*.001*	Measure: 1	*.001*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
255 Parallel	N=69 Mod	**Inflammatory (count)** Baseline counts: 62 (Target) / 57 (Comparator)	Mid (12)	Percent Change*: -23	*NS*	Percent Change*: -42	*.001*	**NS**
		Non-inflammatory (count) Count location: Face.	Mid (12)	Raw count: 61	*.02*	Raw count: 31	*.001*	**NS**
	H.06.05			**Oxytetracycline (oral) + vehicle**		**Tetracycline (topical) + placebo (oral)**		
255 Parallel	N=69 Mod	**Back severity (leeds)** Count location: Back.	Mid (12)	Measure: 0 (0.19)	*.02*	Measure: 0 (0.47)	*NS*	**NS**
		Chest severity (leeds) Count location: Chest.	Mid (12)	Measure: 0 (0.13)	*NS*	Measure: 0 (0.26)	*NS*	**NS**
		Face severity (leeds) Count location: Face.	Mid (12)	Measure: 0	*.001*	Measure: 0	*.01*	**NS**
		Inflammatory (count) Baseline counts: 62 (Target) / 65 (Comparator)	Mid (12)	Percent Change*: -23	*NS*	Percent Change*: -35	*.02*	**NS**
		Non-inflammatory (count) Count location: Face.	Mid (12)	Raw count: 61	*.02*	Raw count: 43	*.003*	**NS**
	H.06.06			**Oxytetracycline**		**Trimethoprim + sulfamethoxazole**		
152 ↑ Parallel	N=16 Mild/mod/sev	**Severity (leeds)** Count location: Entire face chest & back.	Mid (12)	Measure: 4 (2.6)		Measure: 3 (3.3)		**NS**
	H.06.07			**Oxytetracycline**		**Trimethoprim**		
128 ↑ Parallel	N=45 Mild	**Active papules (sqrt count)** Count location: Face(unspecified).	Short (4)	Percent Change*: -38	*.01*	Percent Change*: -46	*.01*	**NS**
		Active pustules (sqrt count) Count location: Face (unspecified.	Short (4)	Percent Change*: -49	*.01*	Percent Change*: -15	*.01*	**NS**
		Back severity (log leeds) Count location: Back.	Short (4)	Measure: 0 (0.08)	*.01*	Measure: 0 (0.08)	*.01*	**NS**
		Chest severity (log leeds) Count location: Chest.	Short (4)	Measure: 0 (0.08)	*.01*	Measure: 0 (0.08)	*.01*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
128 ↑ N=45 Parallel Mild		**Face severity (log leeds)** Count location: Face(unspecified).	Short (4)	Measure: 0 (0.08)	*.01*	Measure: 0 (0.08)	*.01*	**NS**
		Less active papules (sqrt count)	Short (4)	Percent Change*: -26	*.01*	Percent Change*: -13	*.01*	**NS**
		Less active pustules (sqrt count) Count location: Face (unspecified.	Short (4)	Percent Change*: -30	*.01*	Percent Change*: -35	*.01*	**NS**
		Active papules (sqrt count) Count location: Face(unspecified).	Mid (8)	Percent Change*: -47	*.01*	Percent Change*: -61	*.01*	**NS**
		Active pustules (sqrt count)	Mid (8)	Percent Change*: -72	*.01*	Percent Change*: -63	*.01*	**NS**
		Back severity (log leeds) Count location: Back.	Mid (8)	Measure: 0 (0.08)	*.01*	Measure: 0 (0.08)	*.01*	**NS**
		Chest severity (log leeds) Count location: Chest.	Mid (8)	Measure: 0 (0.08)	*.01*	Measure: 0 (0.08)	*.01*	**NS**
		Face severity (log leeds) Count location: Face(unspecified).	Mid (8)	Measure: 0 (0.08)	*.01*	Measure: 0 (0.08)	*.01*	**NS**
		Less active papules (sqrt count)	Mid (8)	Percent Change*: -36	*.01*	Percent Change*: -27	*.01*	**NS**
		Less active pustules (sqrt count) Count location: Face (unspecified.	Mid (8)	Percent Change*: -26	*.01*	Percent Change*: -24	*.01*	**NS**
	H.07.01			**Trimethoprim + sulpamethoxazole**		**Vehicle**		
160 ↑ N=42 Cross-over		**Severity change (witkowski %) [phase 1]**	Short (5)	Measure: -62	*.001*	Measure: -9	*NS*	
		Severity change [phase 2] (witkowski %)	Short (5)	Measure: -43	*.001*	Measure: 35	*NS*	
	H.08.01			**Placebo (topical) + tetracycline hydrochloride (or**		**Placebo (topical) + placebo (oral)**		
23 ↑ N=75 Parallel Mod		**Severity change (cook)** Count location: Entire face-(photos).	Short (6)	Measure: -1 (1.1)		Measure: 0 (1.)		**0.05**
		Severity change (cook))	Long (13	Measure: -2 (1.2)		Measure: -1 (1.2)		**0.05**
	H.08.01			**Tetracycline**		**Placebo**		
201 ↑ N=51 Parallel		**Severity change (pillsbury modified)**	Short (6)	Measure: -1 (0.3)		Measure: 0 (0.3)		**0.001**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
201 ↑ N=51 Parallel		**Severity change (pillsbury modified)**	Mid (12)	Measure: -2 (0.3)		Measure: 0 (0.3)		**0.001**
	H.08.01			**Tetracycline (oral) + vehicle (topical)**		**Vehicle (topical) + placebo (oral)**		
10 N=60 Parallel Mod		**Severity (anderson)** Count location: Butterfly.	Short (6)	Measure: 4	*NS*	Measure: 4	*NS*	**NS**
	H.08.01			**Tetracycline + Placebo**		**Placebo**		
136 N=305 Parallel Mod/sev		**Papules (count)** Count location: Face above jawline. Between P-value: T > P.Baseline counts: 22 (Target) / 11 (Comparator)	Short (6)	Percent Change*: -59		Percent Change*: 24		**0.05**
		Pustules (count) Count location: Face above jawline. Baseline counts: 5 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -60		Percent Change*: -40		**NS**
		Papules (count) Count location: Face above jawline. Between P-value: T > P.Baseline counts: 22 (Target) / 11 (Comparator)	Mid (8)	Percent Change*: -63		Percent Change*: 07		**0.05**
		Pustules (count) Count location: Face above jawline. Between P-value: T > P.Baseline counts: 5 (Target) / 4 (Comparator)	Mid (8)	Percent Change*: -68		Percent Change*: -37		**0.05**
	H.08.01			**Tetracycline + vehicle**		**Vehicle (oral) + vehicle (topical)**		
33 N=87 Parallel Mild		**Inflammatory (count)** Baseline counts: 6 (Target) / 7 (Comparator)	Short (6)	Percent Change*: -51	*.0001*	Percent Change*: -12		**NS***
		Inflammatory (count) Between P-value: compared to clinda.Baseline counts: 6 (Target) / 7 (Comparator)	Mid (8)	Percent Change*: -57	*.0001*	Percent Change*: -12	*NS*	**0.0004**
	H.08.01			**Tetracycline hydrochloride (oral) + placebo**		**Placebo + placebo**		
313 ↑ N=149 Parallel Mild/mod		**Severity (cook)** Count location: Face. Between P-value: with respect to topical.	Short (4)	Measure: 3	*.05*	Measure: 4	*NS*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
313 ↑ Parallel	N=149 Mild/mod	**Severity (cook)** Count location: Face. Between P-value: with respect to topical.	Mid (12)	Measure: 2	*.05*	Measure: 3	*NS*	**NS**
	H.08.02			**Tetracycline (oral) + Placebo (lotion)**		**Clindamycin (lotion) + Placebo (oral)**		
318 Parallel	N=50 Mod	**Overall change/patient (stoughton)**	Short (6)	Measure: 2		Measure: 2		**0.014**
		Papules (count) Count location: Face unspecified. Baseline counts: 18 (Target) / 17 (Comparator)	Short (6)	Percent Change*: -36		Percent Change*: -67		**0.01**
	H.08.02			**Tetracycline + Placebo**		**Clindamycin + Placebo**		
136 Parallel	N=305 Mod/sev	**Papules (count)** Count location: Face above jawline. Between P-value: T > P.Baseline counts: 22 (Target) / 23 (Comparator)	Short (6)	Percent Change*: -59		Percent Change*: -62		**0.05**
		Pustules (count) Count location: Face above jawline. Baseline counts: 5 (Target) / 5 (Comparator)	Short (6)	Percent Change*: -60		Percent Change*: -67		**NS**
		Papules (count) Count location: Face above jawline. Between P-value: T > P.Baseline counts: 22 (Target) / 23 (Comparator)	Mid (8)	Percent Change*: -63		Percent Change*: -68		**0.05**
		Pustules (count) Count location: Face above jawline. Between P-value: T > P.Baseline counts: 5 (Target) / 5 (Comparator)	Mid (8)	Percent Change*: -68		Percent Change*: -76		**0.05**
	H.08.02			**Tetracycline + vehicle**		**Clindamycin + vehicle**		
33 Parallel	N=87 Mild	**Inflammatory (count)** Baseline counts: 6 (Target) / 9 (Comparator)	Short (6)	Percent Change*: -51	*.0001*	Percent Change*: -68	*.0001*	**NS***
		Inflammatory (count) Between P-value: compared to clinda.Baseline counts: 6 (Target) / 9 (Comparator)	Mid (8)	Percent Change*: -57	*.0001*	Percent Change*: -72	*.0001*	**0.0004**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	H.08.02			**Tetracycline + vehicle**		**Clindamycin phosphate + placebo**		
29 ↑ N=20 Parallel Mod		**Nodules (count)** Count location: Entire face. Baseline counts: 1 (Target) / 1 (Comparator)	Short (4)	Percent Change*: -22		Percent Change*: -58		**NS***
		Papules (count) Count location: Entire face. Baseline counts: 27 (Target) / 21 (Comparator)	Short (4)	Percent Change*: -51		Percent Change*: -39		**NS***
		Pustules (count) Count location: Entire face. Baseline counts: 7 (Target) / 5 (Comparator)	Short (4)	Percent Change*: -66		Percent Change*: -22		**NS***
		Nodules (count) Count location: Entire face. Baseline counts: 1 (Target) / 1 (Comparator)	Mid (8)	Percent Change*: -78		Percent Change*: -67		**NS***
		Papules (count) Count location: Entire face. Baseline counts: 27 (Target) / 21 (Comparator)	Mid (8)	Percent Change*: -76		Percent Change*: -70		**NS***
		Pustules (count) Count location: Entire face. Baseline counts: 7 (Target) / 5 (Comparator)	Mid (8)	Percent Change*: -69		Percent Change*: -70		**NS***
	H.08.02			**Tetracycline hydrochloride + placebo**		**Clindamycin + placebo**		
186 ↓ N=44 Parallel Mod		**Closed comedones (count)**	Short (6)	Raw count: 4 (4.)		Raw count: 6 (14.)		**NS***
		Nodules (count)	Short (6)	Raw count: 1 (0.3)		Raw count: 1 (2.)		**NS***
		Open comedones (count)	Short (6)	Raw count: 5 (4.)		Raw count: 7 (18.)		**NS***
		Papules (count)	Short (6)	Raw count: 6 (4.)		Raw count: 7 (9.)		**NS***
		Pustules (count)	Short (6)	Raw count: 6 (4.)		Raw count: 7 (8.)		**NS***
		Closed comedones (count)	Mid (12)	Raw count: 3 (4.)		Raw count: 3 (8.)		**NS***
		Nodules (count)	Mid (12)	Raw count: 0 (0.2)		Raw count: 1 (0.8)		**NS***
		Open comedones (count)	Mid (12)	Raw count: 4 (4.)		Raw count: 4 (8.)		**NS***
		Pustules (count)	Mid (12)	Raw count: 4 (4.)		Raw count: 2 (4.)		**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	H.08.03			**Tetracycline hydrochloride + placebo (topical)**		**Erythromycin + placebo (oral)**		
279 ↑ N=54 Parallel Mod/sev		**Closed comedones change (count)** Baseline counts: 26 (Target) / 22 (Comparator)	Short (4)	Percent change*: -16	*NS*	Percent change*: -31	*.05*	**NS**
		Comedones change (count) Baseline counts: 26 (Target) / 26 (Comparator)	Short (4)	Percent change*: -29	*NS*	Percent change*: -34	*.01*	**NS**
		Inflammatory change (count) Baseline counts: 30 (Target) / 32 (Comparator)	Short (4)	Percent change*: -59	*.001*	Percent change*: -66	*.001*	**NS***
		Open comedone change (count) Baseline counts: 13 (Target) / 5 (Comparator)	Short (4)	Percent change*: -27	*NS*	Percent change*: -47	*NS*	**NS**
		Papules change (count) Baseline counts: 24 (Target) / 26 (Comparator)	Short (4)	Percent change*: -57	*.001*	Percent change*: -66	*.001*	**NS***
		Pustules change (count) Baseline counts: 6 (Target) / 6 (Comparator)	Short (4)	Percent change*: -66	*.01*	Percent change*: -62	*.001*	**NS***
		Closed comedone change (count) Baseline counts: 26 (Target) / 22 (Comparator)	Mid (12)	Percent change*: -31	*.05*	Percent change*: -48	*.001*	**NS**
		Comedones change (count) Baseline counts: 26 (Target) / 26 (Comparator)	Mid (12)	Percent change*: -58	*.05*	Percent change*: -51	*.001*	**NS**
		Inflammatory change (count) Baseline counts: 30 (Target) / 32 (Comparator)	Mid (12)	Percent change*: -45	*.001*	Percent change*: -65	*.001*	**NS***
		Open comedone change (count) Baseline counts: 13 (Target) / 5 (Comparator)	Mid (12)	Percent change*: -56	*NS*	Percent change*: -67	*.01*	**NS**
		Papules change (count) Baseline counts: 24 (Target) / 26 (Comparator)	Mid (12)	Percent change*: -42	*.001*	Percent change*: -63	*.001*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
279 ↑ Parallel	N=54 Mod/sev	**Pustules change (count)** Baseline counts: 6 (Target) / 6 (Comparator)	Mid (12)	Percent change*: -55	*.01*	Percent change*: -70	*.01*	**NS***
	H.08.04			**Placebo (topical) + tetracycline hydrochloride (or**		**Tetracycline hydrochloride (topical) + placebo (or**		
23 ↑ Parallel	N=75 Mod	**Severity change (cook)** Count location: Entire face-(photos).	Short (6)	Measure: -1 (1.1)		Measure: -1 (0.85)		**0.05**
		Severity change (cook))	Long (13	Measure: -2 (1.2)		Measure: -1 (1.4)		**0.05**
	H.08.04			**Tetracycline (oral) + vehicle (topical)**		**Tetracycline (topical) + placebo (oral)**		
10 Parallel	N=60 Mod	**Severity (anderson)** Count location: Butterfly.	Short (6)	Measure: 4	*NS*	Measure: 3	*NS*	**NS**
	H.08.04			**Tetracycline hydrochloride (oral) + placebo**		**Tetracycline hydrochloride (topical) + placebo**		
313 ↑ Parallel	N=149 Mild/mod	**Severity (cook)** Count location: Face. Between P-value: with respect to topical.	Short (4)	Measure: 3	*.05*	Measure: 3	*.05*	**NS**
		Severity (cook)	Mid (12)	Measure: 2	*.05*	Measure: 2	*.05*	**NS**
	H.08.05			**Tetracycline + placebo**		**Azelaic acid + placebo**		
22 ↓ Parallel	N=45 Mod/sev	**Face severity (leeds)**	Short (4)	Measure: 1		Measure: 2		**NS**
		Non-inflammatory (count)	Short (4)	Raw count: 41		Raw count: 44		**NS**
		Total inflammatory (count) Baseline counts: 43 (Target) / 44 (Comparator)	Short (4)	Percent Change*: -35		Percent Change*: -14		**NS**
		Total lesions (count) Baseline counts: 130 (Target) / 128 (Comparator)	Short (4)	Percent Change*: -28		Percent Change*: -16		**NS**
		Total severity (leeds)	Short (4)	Measure: 2		Measure: 4		**NS**
		Face severity (leeds)	Mid (8)	Measure: 1	*NS*	Measure: 1	*NS*	**NS**
		Non-inflammatory (count/median)	Mid (8)	Measure: 30	*sig*	Measure: 42	*sig*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
22 ↓ N=45 Parallel Mod/sev		**Total inflammatory (count)** Baseline counts: 43 (Target) / 44 (Comparator)	Mid (8)	Percent Change*: -49	*sig*	Percent Change*: -32	*sig*	**NS**
		Total lesions (count/median)	Mid (8)	Measure: 90		Measure: 88		**NS**
		Total severity (leeds)	Mid (8)	Measure: 1	*sig*	Measure: 4	*NS*	**NS**
		Face severity (leeds)	Long (24	Measure: 0		Measure: 1		**NS**
		Inflammatory (count)	Long (24	Raw count: 12		Raw count: 28		**NS**
		Non-inflammatory (count)	Long (24	Raw count: 22		Raw count: 28		**NS**
		Total lesions (count) Baseline counts: 130 (Target) / 128 (Comparator)	Long (24	Percent Change*: -54		Percent Change*: -41		**0.05**
		Total severity (leeds)	Long (24	Measure: 1	*.001*	Measure: 2	*.01*	**0.05**
	H.08.05			**Tetracycline hydrochloride**		**Azelaic acid + placebo**		
166 ↑ N=333 Parallel Mild/mod		**Total lesions (count/median)**	Long (20	Measure: 5	*sig*	Measure: 6	*sig*	**NS**
	H.08.05			**Tetracycline hydrochloride + placebo**		**Azelaic acid + placebo**		
167 ↑ N=261 Parallel Mod/sev		**Nodes+cysts (count/median)** Count location: Half face.	Mid (12)	Measure: 5		Measure: 6		**NS**
		Inflammatory (count/median)	Long (24	Measure: 3		Measure: 2		**NS**
		Nodes+cysts (count/median)	Long (24	Measure: 3		Measure: 2		**NS**
	H.08.06			**Tetracycline + vehicle**		**Meclocycline sulfosalicylate + placebo**		
164 ↑ N=60 Parallel Mild/mod		**Closed comedones change (%)**	Short (4)	Percent change: -70		Percent change: -36		**NS**
		Cysts change (%)	Short (4)	Percent change: -80		Percent change: -76		**NS**
		Open comedones change (%)	Short (4)	Percent change: -29		Percent change: 62		**0.02**
		Papules change (%)	Short (4)	Percent change: -64		Percent change: -28		**NS**
		Pustules change (%)	Short (4)	Percent change: -57		Percent change: -41		**NS**
		Total lesions change (%)	Short (4)	Percent change: -67		Percent change: -49		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
164 ↑ N=60 Parallel Mild/mod		**Closed comedones change (%)**	Mid (8)	Percent change: -83		Percent change: -60		**NS**
		Cysts change (%)	Mid (8)	Percent change: -85		Percent change: -92		**NS**
		Open comedones change (%)	Mid (8)	Percent change: -74		Percent change: 21		**0.04**
		Papules change (%)	Mid (8)	Percent change: -63		Percent change: -77		**NS**
		Pustules change (%)	Mid (8)	Percent change: -80		Percent change: -63		**NS**
		Total lesions change (%)	Mid (8)	Percent change: -77		Percent change: -76		**NS**
	H.09.02			**Phenethicillin**		**Placebo**		
312 ↑ N=66 Parallel Mild/mod/sev		**Overall change/patient (score)**	Short (4)	Measure: 3 (4.8)		Measure: 3 (4.8)		**NS**
		Severity change/photo (score) Count location: Entire face.	Short (4)	Measure: 1 (3.1)		Measure: 1 (2.4)		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.